NuVasive poised to take share after disc system approval, says Barrington After NuVasive's PCM cervical disc system was approved by the FDA, Barrington thinks the device leaves the company poised to take share. The firm maintains a $25 target and Outperform rating on the stock.
NuVasive CEO news an incremental positive, says Piper Jaffray Piper Jaffray views NuVasive's naming Greg Lucier as its permanent CEO as an incremental positive despite the executive's lack direct experience in the spine industry. Piper notes its channel checks indicate no meaningful sales force disruption from the CEO transition. It reiterates an Overweight rating on NuVasive with a $56 price target.